Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Panacela Labs, Russia in Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Panacela Labs, Russia in Development Pact

Will develop anti-infective agents for clinical studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cleveland BioLabs and Panacela Labs have signed a contract with the Ministry of Industry and Trade of the Russian Federation for the development of Xenomycins, a family of anti-infective agents. The contract, valued at approximately $4.6 million, was issued under the Russian Federation’s “Pharma 2020” development initiative and provides matching funding for approximately three years to support preclinical and clinical studies.
 
Xenomycins present a new mode of targeting DNA in pathogenic microbes. Preclinical studies demonstrated efficacy of these compounds against a range of parasites and pathogenic fungi.
 
Dmitry Tyomkin, MBA, chief executive officer of Panacela Labs, said, “We are very pleased to have secured additional funding for Xenomycins through this highly competitive program. We believe that our success underscores the quality of our science and ability to generate exciting drug candidates. We expect that the contract will enable us to accelerate our preclinical program and evaluate the potential application of Xenomycins against life threatening infectious diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics